Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 24 Oct 23 EFFECT Notice of effectiveness
- 20 Oct 23 POS AM Prospectus update (post-effective amendment)
- 7 Jun 23 EFFECT Notice of effectiveness
- 31 May 23 POS AM Prospectus update (post-effective amendment)
- 4 Oct 21 EFFECT Notice of effectiveness
- 30 Sep 21 POS AM Prospectus update (post-effective amendment)
- 3 May 21 EFFECT Notice of effectiveness
- 28 Apr 21 POS AM Prospectus update (post-effective amendment)
- 21 Sep 20 EFFECT Notice of effectiveness
-
16 Sep 20 POS AM Prospectus update (post-effective amendment)
- 12 May 20 EFFECT Notice of effectiveness
- 27 Apr 20 POS AM Prospectus update (post-effective amendment)
AKTX similar filings
- 28 Apr 21 Prospectus update (post-effective amendment)
- 27 Apr 21 Prospectus update (post-effective amendment)
- 27 Apr 21 Prospectus update (post-effective amendment)
- 16 Sep 20 Prospectus update (post-effective amendment)
- 14 Sep 20 Prospectus update (post-effective amendment)
- 14 Sep 20 Prospectus update (post-effective amendment)
- 14 Sep 20 Prospectus update (post-effective amendment)
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Akari Therapeutics, Plc.
London, United Kingdom
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 30, 2020, relating to the consolidated financial statements of Akari Therapeutics, Plc. which is incorporated by reference in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
New York, New York
September 15, 2020